Diana Crivellari

Aviano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.

Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.

Journal: Oncotarget

Published: October 30, 2015

Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.

Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients.

Journal: Future oncology (London, England)

Published: February 25, 2015

Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.

Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.

Journal: Tumori

Published: February 18, 2015

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Journal: Journal of translational medicine

Published: January 27, 2015

Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.

Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.

Journal: Tumori

Published: October 10, 2014

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.

Journal: BMC cancer

Published: July 22, 2014

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Journal: The New England journal of medicine

Published: June 03, 2014

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 16, 2014

Prognosis of women with primary breast cancer diagnosed during pregnancy.

Prognosis of women with primary breast cancer diagnosed during pregnancy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 04, 2013

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 08, 2013

Metabolomics biomarkers of frailty in elderly breast cancer patients.

Metabolomics biomarkers of frailty in elderly breast cancer patients.

Journal: Journal of cellular physiology

Published: October 07, 2013

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 31, 2013

Showing 1-12 of 70

Last Updated: 09/26/2026